VEGFA and renal cell adenocarcinoma: In the phase III RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily; Clinicaltrials.gov: NCT00410124) study, vascular endothelial growth factor (VEGF)-refractory patients treated with everolimus versus placebo had longer median progression-free survival (PFS; 4.9 months vs. 1.9 months; hazard ratio [HR], 0.33; P < .001).1